Prosthetic Joint Infection Treatment Market Size, Share, Growth, and Regional Forecast, 2026 - 2033

The global prosthetic joint infection treatment market size is likely to be valued at US$ 110.3 million in 2026 to US$ 154.2 million by 2033 growing at a CAGR of 4.9% during the forecast period from 2026 to 2033.

Prosthetic joint infections (PJIs) require effective therapeutic strategies, such as debridement, antibiotics, and implant retention (DAIR) therapy, due to their complex nature. PJIs can be caused by various factors, including surgical site contamination, hematogenous spread of bacteria, or direct introduction during implant surgery. It occurs when bacteria form a biofilm on the implant surface, making them resistant to immune response and antibiotics.

• Leading Region: North America dominates the prosthetic joint infection treatment market due to high joint replacement volumes, strong infection surveillance systems, advanced hospital infrastructure, and early adoption of DAIR and multidisciplinary care models.
• Fastest Growing Region: Asia Pacific is the fastest-growing region, driven by rising arthroplasty procedures, expanding medical tourism, improving hospital infrastructure, and increasing adoption of advanced antimicrobial and outpatient treatment strategies.
• Dominant Segment: Glycopeptides lead the market, supported by their effectiveness against resistant pathogens such as MRSA, widespread clinical use, and strong role in first-line and combination therapies for PJIs.
• Fastest-Growing Segment: Postoperative infection treatment is the fastest-growing segment, driven by rising revision surgeries, complex biofilm-related infections, and growing demand for advanced antibiotic and implant-retention therapies.

Driver - Growing Emphasis on Employing DAIR Procedures and Multidisciplinary Collaboration

Demand for PJI treatments is driven by several key factors underscoring the importance of effective therapeutic strategies. One significant approach gaining attention is DAIR. This method offers simplicity, shorter recovery time, and reduced physiological damage. Research shows that successful DAIR procedures result in functional outcomes and improved quality of life comparable to uninfected cases. Several variables influence the success of implant retention surgery, including method, antibiotic regimen, host health, and pathogen type.

Biofilms are organized microbial communities with phenotypic variations, fostering bacteria growth resistant to the host immune system and drugs. These biofilms can form on the implanted joint prosthesis, leading to persistent infections that are difficult to treat. This underscores the significance of finding innovative and effective treatment strategies to combat prosthetic joint infections caused by biofilm-forming bacteria.

Achieving success in treating gram-negative infections with DAIR requires early intervention and anti-biofilm antibiotic therapy. The broader scenario underscores the demand for innovative strategies in PJI treatments. PJI is a critical healthcare issue that requires collaboration among a multidisciplinary team of microbiologists, infectious disease experts, rheumatologists, and orthopedic specialists.

Restraints - Limited Success of DAIR Therapy and Antibiotic Resistance Affecting Treatment Outcomes

Demand for prosthetic joint management and PJI treatment faces significant obstacles. DAIR procedures are simpler and less physiologically harmful, but their success can be limited. Patients who experience failed DAIR often require additional surgeries, leading to increased morbidity and costs. Studies suggest that a two-stage exchange after an unsuccessful DAIR may yield poor outcomes, highlighting the need for caution.

Despite DAIR's potential, outcomes can be affected by factors such as the infecting microorganism's antibiotic susceptibility. For instance, Methicillin-resistant S. aureus (MRSA) infections often yield poor DAIR outcomes. Gram-negative microbes also pose challenges, particularly due to antibiotic resistance. The microbial biofilm paradigm, which involves organized microbial communities with drug-resistance, is crucial to understanding DAIR in PJI. Biofilms generate matrices supporting bacterial growth, resisting immune response and treatment. Variables like the method, antibiotic regimen, host condition, and pathogen affect DAIR outcomes. Exchange arthroplasty has a higher chance of success than debridement alone, although methicillin resistance has little effect on how quickly wounds heal.

• As per Open Forum Infectious Diseases, only 55% to 69% of S. aureus infections were successfully treated with DAIR in 2021.

Despite these PJI prevention challenges, applying anti-biofilm antibiotic treatment and considering factors such as symptom duration can enhance DAIR success rates. Addressing antibiotic resistance is pivotal for effective PJI management.

Opportunity - Growth of Intravenous and Oral Step-Down Strategies and Outpatient Care Models

The management of prosthetic joint infections is increasingly shifting toward care pathways that combine initial intravenous antibiotic therapy with timely transition to oral step-down regimens. This approach reduces dependence on prolonged hospitalization, limits catheter-related complications, and offers comparable clinical outcomes when guided by culture results and multidisciplinary oversight. The growing availability of high-bioavailability oral antibiotics, supported by evidence for agents such as linezolid, fluoroquinolones, rifampicin-based combinations, and newer anti-MRSA options, strengthens confidence in step-down models. Hospitals are adopting structured protocols that integrate infectious disease specialists, orthopedic surgeons, and pharmacists to optimize therapy duration, monitoring, and adherence, making the transition from IV to oral treatment a viable, cost-efficient strategy.

At the same time, outpatient parenteral antimicrobial therapy (OPAT) services and home-based infusion care are expanding across many healthcare systems. These models allow stable PJI patients to receive continuation therapy outside the hospital, reducing bed occupancy and improving patient comfort. Ambulatory infusion centers, digitally monitored home-care programs, and portable infusion pumps are enabling the safe administration of long-acting IV antibiotics while lowering overall treatment costs. As payers prioritize value-based care and hospitals work to reduce inpatient burden, the combination of step-down antibiotic strategies and outpatient delivery models presents a major growth opportunity for companies developing targeted antimicrobials, monitoring tools, and specialized infusion services.

By Drug Insights - Extensive Use of Glycopeptides Due to Their Ability to Target Resistant Strains

By drug, glycopeptides are most widely used for PJI treatment and occupied 34% share of the global market in 2025. Glycopeptides are antibiotics, including vancomycin and teicoplanin, essential in managing severe bacterial infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci.

Due to their potent bactericidal effects and coverage against a range of pathogens, glycopeptides are often used as first-line therapies or in combination with other antibiotics for PJI. Their ability to target resistant strains and deliver effective treatment makes them a crucial choice for addressing challenging infections associated with prosthetic joint replacements, ensuring improved patient outcomes and reduced risk of complications.

By Infection Insights - High Demand for Post-operative Infection Treatment Due to the Complexity of the Condition

By infection type, post-operative infections accounted for a 79% share of the global market in 2025. Postoperative infections can cause inflammation and discomfort around the prosthetic joint. Post-operative infections frequently need specialist care, such as antibiotics and, in difficult situations, surgery to remove the infected implant. The complexity and severity of post-operative infections fuel the demand for innovative and effective treatment solutions, leading to high revenue generation for market players.

By Pathogen Insights - Aggressive Nature and Ubiquity of Staphylococcus Aureus Necessitating Specialist Therapies

By pathogen type, Staphylococcus aureus accounted for 36% share of the global market in 2025. Early infections, occurring during the first four weeks following the initial surgery, are typically caused by Staphylococcus aureus due to its aggressive nature and ubiquity in generating infections. This pathogen is known to form biofilms, making infections difficult to treat and prone to recurrence.

Staphylococcus aureus is the most common pathogen, accounting for more than half of all prosthetic joint failures and infections. The slow growth of tiny colony-forming units of Staphylococcus aureus complicates these infections. Effective treatment options for Staphylococcus aureus and associated biofilm are critical, fueling demand for specialist therapies and generating significant income.

By Route of Administration Insights - Direct Bloodstream Delivery through Intravenous Route Leads to Enhanced Antibiotic Efficacy

The intravenous administration route accounted for 68% share of the global market in 2025 due to its direct and rapid delivery of antibiotics into the bloodstream. Intravenous antibiotics ensure effective and targeted treatment, reaching the infection site directly. This route is preferred for severe prosthetic joint infections, ensuring higher antibiotic concentrations are delivered quickly to combat the infection.

Intravenous administration also allows for close monitoring and adjustment of the treatment regimen, contributing to better patient outcomes. Demand for intravenous antibiotics for prosthetic joint infections is driving revenue growth in the market, as healthcare providers prioritize efficient and impactful treatment options.

North America Prosthetic Joint Infection Treatment Market Trends

The U.S. accounted for 33.2% share of the global prosthetic joint infection treatment market in 2025. Growing demand for PJI treatment in the United States can be attributed to healthcare-associated infections (HCAIs) that develop during medical care. HCAIs occur in healthcare facilities after 48 hours of admission or within 30 days of receiving care.

• According to CDC data, about 1 in 31 hospitalized patients in the United States has at least one healthcare-associated infection on any given day. This equates to over 1 million HAI cases annually across hospitals nationwide.

Simple measures such as hand hygiene can prevent HCAIs, reducing morbidity, mortality, and healthcare costs. Recognizing the impact of HCAIs, efforts to promote infection control through guidelines and education, including the WHO's hand-washing initiatives, are vital to address the demand for effective PJI treatment. These factors are responsible for market growth in the United States.

Asia Pacific Prosthetic Joint Infection Treatment Market Trends

Asia Pacific is emerging as one of the most dynamic markets for prosthetic joint infection (PJI) treatment, supported by expanding orthopedic surgical volumes, strong growth in medical tourism, and increasing access to advanced infection-control therapies. India remains a key contributor to regional demand, accounting for 9.2% of the global market in 2025. Its healthcare sector continues to attract patients from overseas due to competitive pricing, availability of skilled surgeons, and improved hospital infrastructure. Government-led initiatives, such as the National Medical & Wellness Tourism Promotion Board, further strengthen India’s position as a preferred destination for joint replacement and revision procedures, thereby raising the need for effective PJI management solutions.

China represents another major growth engine, holding 8.6% of the global market in 2025. The country is experiencing a sharp rise in joint replacement surgeries, with total hip arthroplasty (THA) increasing 2.4-fold and total knee arthroplasty (TKA) rising 5.9-fold, according to the Chinese Medical Journal. The estimated more than 1 million arthroplasty cases performed in 2024 highlight the expanding at-risk population for PJIs. As complications after TJA place significant cost pressure on hospitals, China is rapidly adopting targeted diagnostics, advanced antimicrobial therapies, and implant-retention strategies to manage the growing burden of PJI across its healthcare system.

The prosthetic joint infection treatment industry is highly fragmented, with several competitors offering products and services locally. These businesses are using strategies such as business expansion and innovation to meet patients’ demands and grow their customer base.

Key Industry Developments:

• In October 2025, Peptilogics raised $78 million to advance its experimental prosthetic joint infection therapy. The funding will support a pivotal phase 2/3 clinical trial, marking a significant step toward developing a new treatment option for PJI patients.
• In July 2024, Zimmer Biomet introduced an advanced line of antibiotic-loaded cement spacers engineered to improve infection control and streamline compatibility with existing prosthetic systems. These next-generation spacers are specifically designed to support more effective management of periprosthetic joint infections during two-stage revision procedures.